Clinical specificity of two assays for immunoglobulin kappa and lambda free light chains
Author:
Farnsworth Christopher W.1, Roemmich Brittany1, Spears Grant M.2, Murray David L.2, Dispenzieri Angela2, Willrich Maria Alice V.2
Affiliation:
1. Washington University in St. Louis , St. Louis , MO , USA 2. Department of Laboratory Medicine and Pathology , Mayo Clinic , Rochester , MN , USA
Abstract
Abstract
Objectives
Free light chain (FLC) assays and the ratio of κ/λ are recommended for diagnosis, prognosis and monitoring of plasma cell dyscrasias (PCD). Limited data exists on FLC clinical specificity in patients diagnosed with other conditions.
Methods
We assessed the κ, λ, and κ/λ FLC ratio using the FreeLite assay and the Sebia FLC ELISA assay in 176 patients with clinical presentations of fatigue, anemia, polyclonal hypergammaglobulinemia, joint disorders, kidney disease and non PCD-cancers with no monoclonal protein observed on serum protein electrophoresis or MASS-FIX immunoglobulin isotyping. Manufacturer defined reference intervals (RI) and glomerular filtration rate (GFR) specific RI (renal RI) were utilized.
Results
For the κ/λ ratio, 68.7 % (121/176) of specimens on the FreeLite and 87.5 % (154/176) of specimens on the Sebia assay were within RI. For κ, 68.2 % (120/176) and 72.2 % (127/176) of results were outside RI for FreeLite and Sebia respectively. For λ, 37.5 % (66/176) and 84.1 % (148/176) of FreeLite and Sebia results were outside RI. With FreeLite and Sebia, patients with kidney disease (n=25) had the highest κ/λ ratios. 44 patients (25.0 %) had GFR <60 mL/min/BSA. When renal RI were applied, 13.6 % had a FLCr outside the renal RI with FreeLite, and 4.5 % with Sebia.
Conclusions
In a cohort of patients with signs and symptoms suggestive of PCDs, but ultimately diagnosed with other conditions, Sebia FLC had improved clinical specificity relative to FreeLite, if one was using an abnormal κ/λ ratio as a surrogate for monoclonality.
Publisher
Walter de Gruyter GmbH
Subject
Biochemistry (medical),Clinical Biochemistry,General Medicine
Reference30 articles.
1. Rajkumar, SV, Dimopoulos, MA, Palumbo, A, Blade, J, Merlini, G, Mateos, MV, et al.. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538–48. https://doi.org/10.1016/s1470-2045(14)70442-5. 2. Katzmann, JA, Clark, RJ, Abraham, RS, Bryant, S, Lymp, JF, Bradwell, AR, et al.. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437–44. https://doi.org/10.1093/clinchem/48.9.1437. 3. Rajkumar, SV, Kyle, RA, Therneau, TM, Melton, LJ, Bradwell, AR, Clark, RJ, et al.. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106:812–7. https://doi.org/10.1182/blood-2005-03-1038. 4. Kumar, S, Paiva, B, Anderson, KC, Durie, B, Landgren, O, Moreau, P, et al.. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328–46. https://doi.org/10.1016/s1470-2045(16)30206-6. 5. Muchtar, E, Dispenzieri, A, Gertz, MA, Kumar, SK, Buadi, FK, Leung, N, et al.. Treatment of AL amyloidosis: Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement 2020 update. Mayo Clin Proc 2021;96:1546–77. https://doi.org/10.1016/j.mayocp.2021.03.012.
|
|